
Impact That Matters
Therapeutic Research In Accelerated Discovery (TRIAD)TRIAD = Academia + Government + Industry
TRIAD Partners
Our TRIAD partners include innovative biotech & pharmaceutical companies, award-winning researchers at top-tier universities, and those spanning the drug discovery, drug development, and diagnostics continuum.
Partnerships vary depending on research goals, milestones met in preclinical or clinical development, and strategic alliance agreements.
TRIAD & GRIN
TRIAD Council
The TRIAD Council is composed of CMT thought leaders, experts, and consultants engaged in collaborative planning and decision-making to provide regular guidance and direction to our research strategy. This network of professionals reviews grant proposals, provides expert guidance, and assesses project outcomes to advance therapeutic development for CMT.
Our most recent TRIAD partnerships & initiatives
Click on the logos for more information.
Click on the logos for more information.





HNF participates and supports an advocacy role by providing real-world data to the FDA and other stakeholders. Our critical data facilitates improved knowledge of the lived experience of CMT patients and the advancement of clinical development.
3 New CMT Drug Development Projects
HNF Announces 3 New Drug Partnerships & Pathways Targeting Multiple Forms of CMT.
What is SORD Deficiency: Part 2
Join us for this webinar as we learn more about Sorbitol Dehydrogenase (SORD) Deficiency
A study of the correlation between gait abnormalities, activity monitoring parameters, CMTPedS and a biomarker in children with Charcot-Marie-Tooth disease.
A study of the correlation between gait abnormalities, activity monitoring parameters, CMTPedS and a biomarker in children with Charcot-Marie-Tooth disease.
Applied Therapeutics Announces Initiation of Registrational Phase 2/3 Study of AT-007 in SORD Deficiency
Press Release
Applied Therapeutics Reports Biomarker Data from Pilot Trial of AT-007 in SORD Deficiency
Press release
HNF collaborates with Rarebase on a Drug Discovery Platform to develop treatments for Charcot-Marie-Tooth (CMT)
HNF collaborates with Rarebase on a Drug Discovery Platform to develop treatments for Charcot-Marie-Tooth (CMT)
New Study Measures Progression of CMT1A Nerve Impairment
New Study Measures Progression of CMT1A Nerve Impairment
Interim Analysis Shows Sustained Benefits of PXT3003 for Patients with Charcot-Marie-Tooth Disease Type 1A (‘CMT1A’)
Study Shows Sustained Benefits of PXT3003 for Patients with Charcot-Marie-Tooth Disease Type 1A (‘CMT1A’)
SORD: A Lesson in Repurposing Drugs to Treat Hereditary Neuropathy
Research from a mutation on the SORD gene
TRPV4 Hereditary Neuropathy Patients Connect with Johns Hopkins Experts to Push Research Efforts Forward
Community connected with the TRPV4 HN team at Johns Hopkins